|
1
|
Firestein GS: Evolving concepts of
rheumatoid arthritis. Nature. 423:356–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iwamoto T, Okamoto H, Toyama Y and
Momohara S: Molecular aspects of rheumatoid arthritis: Chemokines
in the joints of patients. FEBS J. 275:4448–4455. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li D, Wang L, Fan Y, Song L, Guo C, Zhu F,
Zhang L and Shi Y: Down-regulation of A20 mRNA expression in
peripheral blood mononuclear cells from patients with systemic
lupus erythematosus. J Clin Immunol. 32:1287–1291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Apostolidis SA, Lieberman LA, Kis-Toth K,
Crispín JC and Tsokos GC: The dysregulation of cytokine networks in
systemic lupus erythematosus. J Interferon Cytokine Res.
31:769–779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Geiler J, Buch M and McDermott MF:
Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des.
17:3141–3154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Silverman N and Maniatis T: NF-kappaB
signaling pathways in mammalian and insect innate immunity. Genes
Dev. 15:2321–2342. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Verma IM, Stevenson JK, Schwarz EM, Van
Antwerp D and Miyamoto S: Rel/NF-kappa B/I kappa B family: Intimate
tales of association and dissociation. Genes Dev. 9:2723–2735.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cavalcante LO, Melo MR, Dinis VG, Castro
RB, Souza BD and Longui CA: Quantitation of glucocorticoid receptor
alpha and NF-κB pathway mRNA and its correlation with disease
activity in rheumatoid arthritis patients. Genet Mol Res.
9:2300–2310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Criswell LA: Gene discovery in rheumatoid
arthritis highlights the CD40/NF-kappaB signaling pathway in
disease pathogenesis. Immunol Rev. 233:55–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Simmonds RE and Foxwell BM: Signalling,
inflammation and arthritis: NF-kappaB and its relevance to
arthritis and inflammation. Rheumatology (Oxford). 47:584–590.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elsby LM, Orozco G, Denton J, Worthington
J, Ray DW and Donn RP: Functional evaluation of TNFAIP3 (A20) in
rheumatoid arthritis. Clin Exp Rheumatol. 28:708–714.
2010.PubMed/NCBI
|
|
12
|
Vereecke L, Beyaert R and van Loo G: The
ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of
immunopathology. Trends Immunol. 30:383–391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coornaert B, Carpentier I and Beyaert R:
A20: Central gatekeeper in inflammation and immunity. J Biol Chem.
284:8217–8221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kingeter LM, Paul S, Maynard SK,
Cartwright NG and Schaefer BC: Cutting edge: TCR ligation triggers
digital activation of NF-kappaB. J Immunol. 185:4520–4524. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Düwel M, Welteke V, Oeckinghaus A, Baens
M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P and Krappmann D:
A20 negatively regulates T cell receptor signaling to NF-kappaB by
cleaving Malt1 ubiquitin chains. J Immunol. 182:7718–7728. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee EG, Boone DL, Chai S, Libby SL, Chien
M, Lodolce JP and Ma A: Failure to regulate TNF-induced NF-kappaB
and cell death responses in A20-deficient mice. Science.
289:2350–2354. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Orozco G, Hinks A, Eyre S, et al Wellcome
Trust Case Control Consortium; YEAR consortium: Combined effects of
three independent SNPs greatly increase the risk estimate for RA at
6q23. Hum Mol Genet. 18:2693–2699. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Musone SL, Taylor KE, Lu TT, Nititham J,
Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S, et
al: Multiple polymorphisms in the TNFAIP3 region are independently
associated with systemic lupus erythematosus. Nat Genet.
40:1062–1064. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thomson W, Barton A, Ke X, Eyre S, Hinks
A, Bowes J, Donn R, Symmons D, Hider S, Bruce IN, et al Wellcome
Trust Case Control Consortium; YEAR Consortium: Rheumatoid
arthritis association at 6q23. Nat Genet. 39:1431–1433. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aletaha D, Neogi T, Silman AJ, Funovits J,
Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP,
Cohen MD, et al: 2010 Rheumatoid arthritis classification criteria:
An American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Arthritis Rheum. 62:2569–2581.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hah YS, Lee YR, Jun JS, Lim HS, Kim HO,
Jeong YG, Hur GM, Lee SY, Chung MJ, Park JW, et al: A20 suppresses
inflammatory responses and bone destruction in human
fibroblast-like synoviocytes and in mice with collagen-induced
arthritis. Arthritis Rheum. 62:2313–2321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boone DL, Turer EE, Lee EG, Ahmad RC,
Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, et
al: The ubiquitin-modifying enzyme A20 is required for termination
of Toll-like receptor responses. Nat Immunol. 5:1052–1060. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Renner F and Schmitz ML: Autoregulatory
feedback loops terminating the NF-kappaB response. Trends Biochem
Sci. 34:128–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato M, Sanada M, Kato I, et al: Frequent
inactivation of A20 in B-cell lymphomas. Nature. 459:712–716. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmitz R, Hansmann ML, Bohle V,
Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I,
Giefing M, Gesk S, et al: TNFAIP3 (A20) is a tumor suppressor gene
in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp
Med. 206:981–989. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heyninck K and Beyaert R: A20 inhibits
NF-kappaB activation by dual ubiquitin-editing functions. Trends
Biochem Sci. 30:1–4. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tavares RM, Turer EE, Liu CL, Advincula R,
Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ, Malynn BA, et al:
The ubiquitin modifying enzyme A20 restricts B cell survival and
prevents autoimmunity. Immunity. 33:181–191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kool M, van Loo G, Waelput W, De Prijck S,
Muskens F, Sze M, van Praet J, Branco-Madeira F, Janssens S, Reizis
B, et al: The ubiquitin-editing protein A20 prevents dendritic cell
activation, recognition of apoptotic cells, and systemic
autoimmunity. Immunity. 35:82–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hövelmeyer N, Reissig S, Xuan NT,
Adams-Quack P, Lukas D, Nikolaev A, Schlüter D and Waisman A: A20
deficiency in B cells enhances B-cell proliferation and results in
the development of autoantibodies. Eur J Immunol. 41:595–601. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Handel ML, McMorrow LB and Gravallese EM:
Nuclear factor-kappa B in rheumatoid synovium. Localization of p50
and p65. Arthritis Rheum. 38:1762–1770. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marok R, Winyard PG, Coumbe A, Kus ML,
Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C,
et al: Activation of the transcription factor nuclear factor-kappaB
in human inflamed synovial tissue. Arthritis Rheum. 39:583–591.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brown KD, Claudio E and Siebenlist U: The
roles of the classical and alternative nuclear factor-kappaB
pathways: Potential implications for autoimmunity and rheumatoid
arthritis. Arthritis Res Ther. 10:2122008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vereecke L, Beyaert R and van Loo G:
Genetic relationships between A20/TNFAIP3, chronic inflammation and
autoimmune disease. Biochem Soc Trans. 39:1086–1091. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Matmati M, Jacques P, Maelfait J,
Verheugen E, Kool M, Sze M, Geboes L, Louagie E, Mc Guire C,
Vereecke L, et al: A20 (TNFAIP3) deficiency in myeloid cells
triggers erosive polyarthritis resembling rheumatoid arthritis. Nat
Genet. 43:908–912. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Boonyasrisawat W, Eberle D, Bacci S, Zhang
YY, Nolan D, Gervino EV, Johnstone MT, Trischitta V, Shoelson SE
and Doria A: Tag polymorphisms at the A20 (TNFAIP3) locus are
associated with lower gene expression and increased risk of
coronary artery disease in type 2 diabetes. Diabetes. 56:499–505.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tejasvi T, Stuart PE, Chandran V, Voorhees
JJ, Gladman DD, Rahman P, Elder JT and Nair RP: TNFAIP3 gene
polymorphisms are associated with response to TNF blockade in
psoriasis. J Invest Dermatol. 132:593–600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maxwell JR, Gowers IR, Kuet KP, Barton A,
Worthington J and Wilson AG: Expression of the autoimmunity
associated TNFAIP3 is increased in rheumatoid arthritis but does
not differ according to genotype at 6q23. Rheumatology (Oxford).
51:1514–1515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Plenge RM, Cotsapas C, Davies L, Price AL,
de Bakker PI, Maller J, Pe'er I, Burtt NP, Blumenstiel B, DeFelice
M, et al: Two independent alleles at 6q23 associated with risk of
rheumatoid arthritis. Nat Genet. 39:1477–1482. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Frenzel LP, Claus R, Plume N, Schwamb J,
Konermann C, Pallasch CP, Claasen J, Brinker R, Wollnik B, Plass C,
et al: Sustained NF-kappaB activity in chronic lymphocytic leukemia
is independent of genetic and epigenetic alterations in the TNFAIP3
(A20) locus. Int J Cancer. 128:2495–2500. 2011. View Article : Google Scholar : PubMed/NCBI
|
